Seng and Xeljanz drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Seng (ginseng, panax) and Xeljanz (tofacitinib citrate). Common drug interactions include abdominal pain upper among females and blood iron decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Seng and Xeljanz. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Seng?

Seng has active ingredients of ginseng, panax. eHealthMe is studying from 1,152 Seng users. Check the latest studies of Seng.

What is Xeljanz?

Xeljanz has active ingredients of tofacitinib citrate. It is often used in rheumatoid arthritis. eHealthMe is studying from 239,081 Xeljanz users. Check the latest studies of Xeljanz.



On Jul, 26, 2026

12 people who take Seng and Xeljanz together, and have interactions are studied.

Seng and Xeljanz drug interactions.

What are the common drug interactions of Seng and Xeljanz, by gender? *:

female:

  1. Abdominal pain upper
  2. Alopecia (absence of hair from areas of the body)
  3. Anti-cyclic citrullinated peptide antibody positive
  4. Arthralgia (joint pain)
  5. Arthropathy
  6. Asthenia (weakness)
  7. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  8. Blood cholesterol increased
  9. Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder)
  10. Confusional state

male:

  1. Blood iron decreased
  2. Colitis ulcerative (inflammation of colon with ulcer)
  3. Cough
  4. Hunger

What are the common drug interactions of Seng and Xeljanz, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Blood iron decreased
  2. Colitis ulcerative (inflammation of colon with ulcer)
  3. Hunger

40-49:

  1. Abdominal discomfort
  2. Abdominal pain
  3. Abdominal pain upper
  4. Alopecia (absence of hair from areas of the body)
  5. Anti-cyclic citrullinated peptide antibody positive
  6. Arthralgia (joint pain)
  7. Arthropathy
  8. Asthenia (weakness)
  9. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  10. Blood cholesterol increased

50-59:

n/a

60+:

  1. Pain
  2. Body height decreased
  3. Barrett's oesophagus (barrett's oesophagus is a disorder in which the lining of the oesophagus (the tube that carries food from the throat to the stomach) is damaged by stomach acid and changed to a lining similar to that of the stomach)
  4. Cough
  5. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  6. Stomatitis (inflammation of mucous membrane of mouth)
  7. Thrombosis (formation of a blood clot inside a blood vessel)
  8. Tooth infection
  9. Compression fracture (fracture due to pressure caused by injury)
  10. Fatigue (feeling of tiredness)

* Approximation only. Some reports may have incomplete information.

Do you take Seng and Xeljanz?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Seng and Xeljanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Seng:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Xeljanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Seng and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Xeljanz and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ginseng, panax and tofacitinib citrate (the active ingredients of Seng and Xeljanz, respectively), and Seng and Xeljanz (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: